[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597210":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":32,"locations":43,"responsibleParty":57,"collaborators":31,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":31,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":31,"overallStatus":81,"whyStopped":31,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Hayat Abad Medical Complex, Peshawar","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A in which the patient will recieve PUVA therapy","OTHER","The Study will have two groups and in this group patients will recieve Psoralen combined with UVA (PUVA) therapy",[13],"Drug: Group A recieving PUVA therapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B in which the patient will be given Tofacitinib 5mg","This study will have two groups and this group will recieve tablet tofacitinib 5mg",[18],"Drug: Group B receiving Tablet Tofacitinib",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Group A recieving PUVA therapy","This group A will recieve PUVA therapy twice weekly for 6 months",[9],[26],"Psoralen combined with Ultraviolet A",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Group B receiving Tablet Tofacitinib","This group will be given tablet Tofacitinib 5mg twice daily for 6 months",[15],null,[33,38],{"name":34,"role":35,"phone":36,"phoneExt":36,"email":37},"Sana Zaman Sana Zaman, FCPS Part II","CONTACT","92 317 6030615","zamansana16@gmail.com",{"name":39,"role":35,"phone":40,"phoneExt":41,"email":42},"Kamran Ullah Ullah, FCPS Part II","03429149403","0342-9149403","kamran.ullah1983@gmail.com",[44],{"facility":45,"status":31,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":31},"MTI-HMC Peshawar","Peshawar","Khyber Pukhtunkhwa","25000","Pakistan","PK",{"type":52,"coordinates":53},"Point",[54,55],71.57849,34.008,{"lat":55,"lon":54},{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"PRINCIPAL_INVESTIGATOR","Syeda Sana Zaman","Trainee Medical Officer","100597210","early-phase-1-comparison-of-efficacy-and-safety-psoralen-combined-with-ultraviolet-a-puva-vs-tofacitinib-in-the-treatment-of-generalized-vitiligo-100597210",false,"NCT07055529","Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.","(PUVA)","Inclusion Criteria:\n\n* • Patients of either gender aged 18-60 years, diagnosed with generalized vitiligo (depigmentation affecting more than 10% of the body surface area).\n\n  * Stable vitiligo (no new lesions or progression of existing lesions in the last three months).\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity or allergies to Psoralen or Tofacitinib in order to prevent adverse reactions that could compromise patient safety and interfere with treatment efficacy assessment.\n* Pregnant or lactating women in order to ensure fetal and neonatal safety, as the effects of Psoralen and Tofacitinib on pregnancy and breastfeeding are not well studied and could pose potential risks.",true,"ALL","18 Years","60 Years",{"count":73,"type":74},64,"ESTIMATED","INTERVENTIONAL",[77],"EARLY_PHASE1","This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.",[80],"Vitiligo, Generalized","NOT_YET_RECRUITING","2026-01-29",{"date":84,"type":85},"2026-01-30","ACTUAL",{"date":87,"type":74},"2026-06-01",{"date":89,"type":74},"2026-12-31",{"name":5,"class":6},1]